Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

CRRD ID: 3910
Species: Rattus norvegicus
CRRD Object: Gene
Symbol: Tshb
Name: thyroid stimulating hormone subunit beta
Acc ID: CHEBI:63637
Term: vemurafenib
Definition: A pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases.
Chemical ID: MESH:C551177
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
QualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
multiple interactionsISORGD:7326056480464CTD[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA, [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA, [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA, [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA, BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA], BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA], BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA], BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA], BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]], BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]], BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]], BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]], TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein], Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]], Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA], Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA], Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA], Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]

PMID:26751190
Go Back to source page   Continue to Ontology report

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.